Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: A secondary analysis of 4 studies in major depressive disorder

Journal of Clinical Psychiatry

Volumn 71, Issue 11, 2010, Pages 1482-1487

  Lobello, Kasia W ^a   Preskorn, Sheldon H ^b   Guico Pabia, Christine J ^a   Jiang, Qin ^a   Paul, Jeffrey ^a   Nichols, Alice I ^a   Patroneva, Albena ^a,c   Ninan, Philip T ^a  

^a PFIZER INC   (United States)

^b University of Montreal   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6; DESVENLAFAXINE; PLACEBO; VENLAFAXINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FISHER EXACT TEST; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PREDICTION; PRIORITY JOURNAL; REMISSION; SECONDARY ANALYSIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; STUDENT T TEST; SWEATING; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; BIPOLAR DISORDER; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954677804     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04773blu     Document Type: Article

References (49)

1. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(1):23-37.
2. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004;25(4):193-200.
3. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47(1):75-85.
4. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3(2):229-243.
5. Gaedigk A, Bradford LD, Marcucci KA, et al. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002;72(1):76-89.
6. Gaedigk A. Interethnic differences of drug-metabolizing enzymes. Int J Clin Pharmacol Ther. 2000;38(2):61-68.
7. Bradford LD, Kirlin WG. Polymorphism of CYP2D6 in black populations: implications for psychopharmacology. Int J Neuropsychopharmacol. 1998;1(2):173-185.
8. Otton SV, Ball SE, Cheung SW, et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996;41(2):149-156.
9. Shams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006;31(5):493-502.
10. Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit. 2000;22(2):202-208.
11. Nichols AI, Lobello K, Guico-Pabia C, et al. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status. J Clin Psychopharmacol. 2009;29(4):383-386.
12. Borgherini G, Conforti D, Scarso C, et al. Is it possible to early predict venlafaxine response in major depression? [poster]. Presented at the 16th Congress of the European College of Neuropsychopharmacology; September 20-24, 2003; Prague, Czech Republic
13. Grasmäder K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004;60(5):329-336.
14. McAlpine DE, O'Kane DJ, Black JL, et al. Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin Proc. 2007; 82(9):1065-1068.
15. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clin Pharmacol Ther. 2004;75(5):386-393.
16. Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry. 1998;59(3):116-122.
17. Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry. 1997;9(3): 157-164.
18. Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry. 1997;58(9):393-398.
19. Mendels J, Johnston R, Mattes J, et al. Efficacy and safety of bid doses of venlafaxine in a dose-response study. Psychopharmacol Bull. 1993; 29(2):169-174.
20. Hamilton M. Hamilton Rating Scale for Depression (Ham-D). In: Rush AJ, Pincus HA, First MB, et al, eds. Handbook of Psychiatric Measures. 1st ed. Washington, DC: American Psychiatric Association; 2000:526-529.
21. Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatr Scand. 1975;51(3):161-170.
22. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.
23. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication ADM 76-338. Rockville, Md: National Institute of Mental Health; 1976:217-222.
24. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. http://medicine.iupui.edu/flockhart/table.htm. Accessed May 22, 2008.
25. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178(3):234-241.
26. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry. 2002;52(12):1166-1174.
27. Whyte EM, Romkes M, Mulsant BH, et al. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Int J Geriatr Psychiatry. 2006;21(6):542-549.
28. Montgomery SA, Roy D, Wynne-Willson S, et al. Plasma levels and clinical response with imipramine in a study comparing efficacy with mianserin and nomifensine. Br J Clin Pharmacol. 1983;15(suppl 2): 205S-211S.
29. Kasper S, Dötsch M, Kick H, et al. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol. 1993;3(1):13-21.
30. Ilett KF, Blythe TH, Hackett LP, et al. Plasma concentrations of dothiepin and its metabolites are not correlated with clinical efficacy in major depressive illness. Ther Drug Monit. 1993;15(5):351-357.
31. Spina E, Gitto C, Avenoso A, et al. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol. 1997;51(5):395-398.
32. Gex-Fabry M, Balant-Gorgia AE, Balant LP, et al. Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol. 2004;59(12):883-891.
33. Preskorn SH. To monitor or not to monitor? J Pract Psych Behav Hlth. 1996;2(3):172-175.
34. Preskorn SH. To monitor or not to monitor, II: the glass is more than half full. J Pract Psychiatry Behav Health. 1996;2(5):307-310.
35. Fogelman SM, Schmider J, Venkatakrishnan K, et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999;20(5):480-490.
36. Hermann M, Hendset M, Fosaas K, et al. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N- desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. Eur J Clin Pharmacol. 2008;64(5):483-487.
37. Muth EA, Moyer JA, Haskins JT, et al. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res. 1991;23(2):191-199.
38. Siegle I, Fritz P, Eckhardt K, et al. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics. 2001;11(3):237-245.
39. Yu AM, Idle JR, Byrd LG, et al. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics. 2003;13(3):173-181.
40. Ozdemir V, Gunes A, Dahl ML, et al. Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness? Pharmacogenomics. 2006;7(8):1199-1210.
41. Mihara K, Otani K, Tybring G, et al. The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. J Clin Psychopharmacol. 1997;17(6):467-471.
42. Bertilsson L, Alm C, De Las Carreras C, et al. Debrisoquine hydroxy lation polymorphism and personality. Lancet. 1989;1(8637):555.
43. Kang RH, Wong ML, Choi MJ, et al. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1317-1321.
44. Kim H, Lim SW, Kim S, et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA. 2006;296(13):1609-1618.
45. Kirchheiner J, Nickchen K, Sasse J, et al. A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J. 2007;7(1):48-55.
46. Yoshida K, Takahashi H, Higuchi H, et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry. 2004;161(9):1575-1580.
47. Yoshida K, Higuchi H, Takahashi H, et al. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum Psychopharmacol. 2008;23(2):121-128.
48. Szegedi A, Rujescu D, Tadic A, et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2005;5(1):49-53.
49. Tadić A, Rujescu D, Müller MJ, et al. A monoamine oxidase B gene variant and short-term antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1370-1377.